INTERNATIONAL PERSPECTIVE: Management of chemotherapy-induced febrile neutropenia among adult oncology patients: A review

Audai Nader Saeed, Nijmeh Al-Atiyyat

Abstract


The aim of this literature review is to investigate the safest and most appropriate actions for the management of chemotherapy-induced febrile neutropenia. A literature search was undertaken, including major computerized electronic databases (PUBMED, SPRINGER, and WILEY). All studies that discuss colony stimulating factor plus antibiotics versus antibiotics or colony stimulating factors alone for the treatment of febrile neutropenia in adult oncology patients were sought. A review of the selected studies was performed. Most studies focus on the prompt assessment and management for oncology patients who are experiencing febrile neutropenia by using appropriate antibiotics and highlight the importance of using antibiotics and colony stimulating factor in the management of chemotherapy-induced neutropenic fever.

Key words: febrile neutropenia, chemotherapy, management, oncology patients


Full Text:

PDF

References


Bhardwaj, A.S., & Navada, S.C. (2013). Management of chemotherapy-induced neutropenic fever. Hospital Practice, 41(1), 96–108. doi:10.3810/hp.2013.02.1015

Biswal, S., & Godnaik, C. (2013). Incidence and management of infections in patients with acute leukemia following chemotherapy in general wards. Ecancer Medical Science, 7(310), 1–16. doi:10.3332/ecancer.2013.310

De Naurois, J., Novitzky-Basso, I., Gill, M.J., Marti, F.M., Cullen, M.H., & Roila, F. (2010). Management of febrile neutropenia: ESMO clinical practice guidelines. Annals of Oncology, 21(5), 252–256. doi:10.1093/annonc/mdq196

Doshi, B.D., Pandya, N.M., Shah, C.A., Gupta, A.K., & Makwana, M.V. (2012). Chemotherapy-induced neutropenia in cancer patients with solid tumours in India. Der Pharmacia Lettre, 4(2), 584–590.

Gupta, S., Singh, P.K., Bhatt, M.L., Pant, M.C., Gupta, R., & Negi, M.P. (2010). Efficacy of granulocyte colony stimulating factor as a secondary prophylaxis along with full-dose chemotherapy following a prior cycle of febrile neutropenia. Bioscience Trends, 4(5), 273–278.

Khalafallah, A., Maiwald, M., Hannan, T., Abell, S., Staker, J., & Supperamohan, A. (2012). Early implementation of antifungal therapy in the management of febrile neutropenia is associated with favourable outcome during induction chemotherapy for acute leukaemias. Internal Medicine Journal, 42(2), 131–136.

Mahmood, S., & Tariq, A. (2014). Comparison of antibiotics; granulocyte colony-stimulating factor in children with chemotherapy–induced febrile neutropenia. Professional Medical Journal, 21(4), 667–671.

Mathew, V.V. (2012). Febrile neutropenia. Kerala Nursing Forum, 7, 5–15.

National Chemotherapy Advisory Group (2009). Chemotherapy services in England: Ensuring quality and safety: A report from the National Chemotherapy Advisory Group. Retrieved from http://ncat.nhs.uk/sites/default/files/NCAG%20Report.pdf

National Institute for Health and Clinical Excellence (2012). Neutropenic sepsis scope. Retrieved from http://guidance.nice.org.uk/CG/Wave23/11/Scope/pdf/English, NICE, 2012.

Perron, T., Emara, M., & Ahmed, S. (2014). Time to antibiotics and outcomes in cancer patients with febrile neutropenia. BMC Health Services Research, 14(1), 162.

Rosa, R.G., & Goldani, L.Z. (2014). Impact of time to antibiotic administration on mortality in patients with febrile neutropenia: A cohort study. Antimicrobial Agents and Chemotherapy, AAC-02561.

Schouten, H.C., (2006). Neutropenia management. Annals of Oncology, 17. doi:10.1093/annonc/mdl243

Simmons, T. (2012). Prevention and management of neutropenic sepsis in cancer patients. British Medical Journal, 2012, 345.

Villafuerte-Gutierrez, P., Villalon, L., Losa, J.E., & Henriquez-Camacho, C. (2014). Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: A critical review and update. Advances in Hematology. 1–9.

doi:org/10.1155/2014/986938

Weycker, D., Barron, R., Kartashov, A., Legg, J., & Lyman, G.H. (2014). Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. Journal of Oncology Pharmacy Practice, 20(3), 190–198. doi:10.1177/1078155213492450

Wright, J.D., Neugut, A.I., Ananth, C.V., Lewin, S.N., Wilde, E.T., Lu, Y.S., ... & Hershman, D.L. (2013). Deviations from guideline-based therapy for febrile neutropenia in cancer patients and their effect on outcomes. JAMA internal medicine, 173(7), 559–568.


Refbacks

  • There are currently no refbacks.